814 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
AMGN Amgen Inc. $200.81 $129.98B N/A
Article Searches
What's in the Cards for Amarin (AMRN) This Earnings Season? http://www.zacks.com/stock/news/775151/whats-in-the-cards-for-amarin-amrn-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-775151 Feb 20, 2020 - Amarin's (AMRN) fourth-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.
Can Biotech ETFs Gain on Mixed Q4 Earnings Results? http://www.zacks.com/stock/news/760880/can-biotech-etfs-gain-on-mixed-q4-earnings-results?cid=CS-ZC-FT-etf_news_and_commentary-760880 Feb 11, 2020 - Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q4 earnings releases.
J&J Files Application for Darzalex Label Expansion With FDA http://www.zacks.com/stock/news/760090/jj-files-application-for-darzalex-label-expansion-with-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-760090 Feb 11, 2020 - J&J (JNJ) seeks approval for new Darzalex combo regimen in the United States to treat relapsed/refractory multiple myeloma patients who have received one to three prior lines of therapy.
Roche Reports Disappointing Data on Alzheimer's Disease Drug http://www.zacks.com/stock/news/758962/roche-reports-disappointing-data-on-alzheimers-disease-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-758962 Feb 10, 2020 - Roche's (RHHBY) Alzheimer's disease drug fails to meet primary endpoint in a phase II/III study.
Top Stock Research Reports for Alphabet, Roche & Amgen http://www.zacks.com/research-daily/754489/top-stock-research-reports-for-alphabet-roche-amgen?cid=CS-ZC-FT-research_daily-754489 Feb 07, 2020 - Top Stock Research Reports for Alphabet, Roche & Amgen
Teva (TEVA) to Report Q4 Earnings: What's in the Cards? http://www.zacks.com/stock/news/754447/teva-teva-to-report-q4-earnings-whats-in-the-cards?cid=CS-ZC-FT-analyst_blog|earnings_preview-754447 Feb 07, 2020 - Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q4 sales.
Bristol-Myers' (BMY) Q4 Earnings & Revenues Beat Estimates http://www.zacks.com/stock/news/753057/bristol-myers-bmy-q4-earnings-revenues-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-753057 Feb 06, 2020 - Bristol-Myers (BMY) beats both earnings and sales estimates in the fourth quarter, primarily on robust sales of Eliquis and acquisition of Celgene.
Sanofi (SNY) Q4 Earnings Top, Sales Miss, Dupixent Strong http://www.zacks.com/stock/news/752611/sanofi-sny-q4-earnings-top-sales-miss-dupixent-strong?cid=CS-ZC-FT-analyst_blog|earnings_article-752611 Feb 06, 2020 - Sanofi (SNY) reports mixed fourth-quarter results with strong Specialty Care and Vaccines sales but soft Consumer Healthcare sales
Biotech Stock Roundup: Earnings Updates From VRTX, AMGN, GILD; AIMT Gains FDA Nod http://www.zacks.com/stock/news/750705/biotech-stock-roundup-earnings-updates-from-vrtx-amgn-gild-aimt-gains-fda-nod?cid=CS-ZC-FT-analyst_blog|stock_roundup-750705 Feb 05, 2020 - Many biotech bigwigs came out with their fourth-quarter numbers in the past week.
Teva's Two Pivotal Studies on Ajovy in Japan Meet Goal http://www.zacks.com/stock/news/748888/tevas-two-pivotal-studies-on-ajovy-in-japan-meet-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-748888 Feb 04, 2020 - Teva (TEVA) posts positive results from two phase II/III studies on Ajovy for treating patients with chronic and episodic migraine in Japan.

Pages: 123456...82

Page 1>